Table 2.
Response to therapy
| Arm | n | No. of patients achieving response | Response rate (95% CI) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| CR | CRu | PR | SD | PD | NE | %CR | ORR | |||
| Arm C | Eligible | 32 | 19 | 2 | 9 | 1 | 0 | 1 | 66% (47–81%) | 94% (79–99%) |
| 21 | ||||||||||
| 30 | ||||||||||
| Enrolled | 34 | 21 | 2 | 10 | 1 | 0 | 0 | 68% (50–83%) | 97% (85–100%) | |
| 23 | ||||||||||
| 33 | ||||||||||
| Arm S | Eligible | 34 | 22 | 1 | 10 | 0 | 0 | 1 | 68% (50–83%) | 97% (85–100%) |
| 23 | ||||||||||
| 33 | ||||||||||
| Enrolled | 35 | 21 | 1 | 10 | 0 | 0 | 2 | 66% (44–81%) | 94% (81–99%) | |
| 23 | ||||||||||
| 33 | ||||||||||
Response to each therapy was evaluated according to the International Workshop Criteria for Non‐Hodgkin's Lymphoma. CI, confidence interval; CR, complete response; CRu, complete response/unconfirmed; NE, not evaluative due to insufficient follow‐up; ORR, overall response rate; PD, progressive disease; PR, partial response; SD, stable disease.